Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTRobert Izquierdo, The Motley FoolMon, June 29, 2026 at 3:06 PM GMT+2 4 min readJason V. Coloma, Chief Executive Officer of Maze Therapeutics (NASDAQ:MAZE), reported the indirect sale of 27,858 shares of common stock over three open-market transactions on June 22 and June 23, 2026, according to the SEC Form 4 filing.Transaction summaryMetricValueShares sold (indirect)27,858Transaction value~$725,000Post-transaction shares (direct)0Post-transaction shares (indirect)345,009Transaction value based on SEC Form 4 weighted average reported price ($26.04).Key questionsWhat proportion of Coloma's indirect position was affected by this transaction?This sale reduced indirect holdings from 372,867 to 345,009 shares, with no direct ownership shares reported in this filing.Were the shares sold directly or through trusts, and which entities were involved?All shares sold were held indirectly through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, as disclosed in the filing; no shares were sold from direct ownership.How does this transaction compare to Coloma's recent trading activity?Since May of 2026, Coloma has made four sell transactions, totaling 69,003 shares sold, with this disposition being the largest single transaction by share count and reflecting a capacity-driven cadence as indirect holdings declined.What context does the current valuation provide for this sale?The average transaction price was around $26.04 per share, with Maze Therapeutics shares closing at $26.41 on June 23, 2026, and the stock up 134.38% over the past year as of the transaction date.Company overviewMetricValuePrice (as of market close June 23, 2026)$26.41Market capitalization$1.57 billionRevenue (TTM)$20.00 millionNet income (TTM)($122.54 million)* 1-year performance is calculated using June 23, 2026 as the reference date.Company snapshotMaze Therapeutics develops small molecule precision medicines targeting kidney and metabolic diseases, with lead assets in phase II clinical trials addressing APOL1 kidney disease, phenylketonuria, and Pompe disease.It has licensing agreements and collaborative research partnerships with pharmaceutical and biotechnology businesses.The company serves biopharmaceutical partners and targets patients with rare and chronic kidney and metabolic disorders in the United States.Maze Therapeutics is a clinical-stage biotechnology company focused on developing precision small molecule therapies for kidney and metabolic diseases. The company's strategy leverages proprietary discovery platforms and strategic collaborations to advance a pipeline of assets addressing significant unmet medical needs.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info